Biotech Companies in Cambridge, Massachusetts

179 biotech companies in Cambridge, Massachusetts, United States, compiled from public registers and the BioBridgeX marketplace. Open any company for its headquarters, FDA-registered sites and public filings.

Biotech Companies in Cambridge, Massachusetts

179 companies, best-documented first.

Show the first companies

  1. Nano Terra, Inc.Cambridge, Massachusetts, United States
  2. Acceleron Pharma IncCambridge, Massachusetts, United States
  3. Angiex, Inc.Cambridge, Massachusetts, United States
  4. Axoft, Inc.Cambridge, Massachusetts, United States
  5. Convergent Therapeutics, Inc.Cambridge, Massachusetts, United States
  6. Kelonia Therapeutics, Inc.Cambridge, Massachusetts, United States
  7. Prime Medicine, Inc.Nasdaq: PRMECambridge, Massachusetts, United States
  8. Skylark Bio, Inc.Cambridge, Massachusetts, United States
  9. Tasca Therapeutics CorpCambridge, Massachusetts, United States
  10. Novopyxis Inc.Cambridge, Massachusetts, United States
  11. Checkmate Pharmaceuticals, Inc.Cambridge, Massachusetts, United States
  12. Dimension Therapeutics, Inc.Cambridge, Massachusetts, United States
  13. Neon Therapeutics, Inc.Cambridge, Massachusetts, United States
  14. Neuroelectrics, Inc.Cambridge, Massachusetts, United States
  15. Syndevrx IncCambridge, Massachusetts, United States
  16. Xeno Biosciences Inc.Cambridge, Massachusetts, United States
  17. Scholar Rock LLCCambridge, Massachusetts, United States
  18. Arbor Biotechnologies, Inc.Cambridge, Massachusetts, United States
  19. Celsius Therapeutics, Inc.Cambridge, Massachusetts, United States
  20. Iterative Scopes, Inc.Cambridge, Massachusetts, United States

Showing 60 of 179 companies

Other life science companies in Cambridge, Massachusetts

Outsourcing a study or a manufacturing run?

Describe the work once and compare quotes from CROs and CDMOs on BioBridgeX. Free for buyers.

Compare quotes

Counts include published company profiles only and update daily. Data licences

Is a company missing or wrong? Tell us.